GERN - Geron Corporation
1.3501 -0.01 (-0.73%)
After hours: 4:01PM EDT
| Previous Close | 1.4400 |
| Open | 1.4200 |
| Bid | 1.3500 x 42300 |
| Ask | 1.3600 x 21500 |
| Day's Range | 1.3500 - 1.4500 |
| 52 Week Range | 0.9500 - 6.9900 |
| Volume | 1,131,943 |
| Avg. Volume | 1,627,250 |
| Market Cap | 259.865M |
| Beta (3Y Monthly) | 2.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2000 |
| Earnings Date | May 4, 2017 - May 8, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.88 |
- GlobeNewswire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 240,000 shares of Geron common stock as inducements to two newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on August 21, 2019 at an exercise price of $1.42 per share, which is equal to the closing price of Geron common stock on the date of grant. Each stock option granted has a 10-year term and vests over four years, with 12.5% of the shares underlying the option vesting on the six-month anniversary of commencement of employment and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.
- Simply Wall St.
A Spotlight On Geron Corporation's (NASDAQ:GERN) Fundamentals
Geron Corporation (NASDAQ:GERN) is a stock with outstanding fundamental characteristics. When we build an investment...
- GlobeNewswire
Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
Geron Corporation (GERN) today announced the opening of patient screening and enrollment for the Phase 3 portion of IMerge to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS). “The start of the Phase 3 portion of IMerge is a significant milestone for Geron and imetelstat,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer.
- Thomson Reuters StreetEvents
Edited Transcript of GERN earnings conference call or presentation 1-Aug-19 8:30pm GMT
Q2 2019 Geron Corp Earnings Call
Motley FoolGeron Corporation (Delaware) (GERN) Q2 2019 Earnings Call Transcript
GERN earnings call for the period ending June 30, 2019.
- Zacks
Geron (GERN) Stock Up Despite Q2 Earnings & Sales Miss
Geron (GERN) posts a wider-than-expected loss in second-quarter 2019. Operating expenses increase on a year-over-year basis.
- Motley Fool
What You'll Want to Know About Geron's Q2 Results
There wasn't much good news for the small biotech in Q2. But Geron continues to plug away with its imetelstat program.
- Zacks
Geron (GERN) Reports Q2 Loss, Misses Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of -33.33% and -49.75%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Geron Corporation Reports Second Quarter 2019 Financial Results and Recent Events
MENLO PARK, Calif., Aug. 01, 2019 -- Geron Corporation (Nasdaq: GERN) today reported financial results for the second quarter ended June 30, 2019, and recent events. The.
- GlobeNewswire
Geron to Announce Second Quarter Financial Results on August 1, 2019
Geron Corporation (GERN) today announced that it will release its second quarter 2019 financial results after the market closes on Thursday, August 1, 2019 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m. ET the same day. Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
- Zacks
Earnings Preview: Geron (GERN) Q2 Earnings Expected to Decline
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Geron Enhances Oncology Expertise to Advance Corporate Objectives
Geron Corporation (GERN) today announced the appointments of Sharon McBain as Vice President, Global Regulatory Affairs and Lynn Bodarky as Vice President, Business Development. As Vice President, Global Regulatory Affairs, Ms. McBain will be responsible for global regulatory strategy development, oversight of regulatory submissions, and interactions with the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and other ex-U.S. health authorities.
- Motley Fool
Why Geron Corporation Stock Bolted Higher in the First Half of 2019
Geron's stock has rebounded nicely in the first half of 2019.
- Simply Wall St.
Such Is Life: How Geron (NASDAQ:GERN) Shareholders Saw Their Shares Drop 58%
Investing in stocks comes with the risk that the share price will fall. And there's no doubt that Geron Corporation...
- GlobeNewswire
Geron Appoints Vice President, Human Resources
Geron Corporation (GERN) today announced the appointment of Shannon Odam as Vice President, Human Resources. Ms. Odam joins other recently recruited senior leadership to further strengthen the organization as it expands its operations to support the planned opening of the Phase 3 portion of IMerge in lower risk myelodysplastic syndromes for screening and enrollment in the summer of 2019. As Vice President, Human Resources, Ms. Odam will lead all aspects of a comprehensive human resources function, including oversight of policies and operations for leadership and talent management, training, organizational development, operational effectiveness and workforce planning.
- GlobeNewswire
Geron Reports Two Imetelstat Data Presentations at European Hematology Association Annual Congress
Updated 8-week RBC-TI rate for the Phase 2 portion of IMerge increased to 42%, from 37% in December 2018Updated 24-week RBC-TI rate for the Phase 2 portion of IMerge increased.
- GlobeNewswire
Geron to Webcast KOL Event on June 25, 2019
Geron Corporation (GERN) today announced that the Company will webcast an event on June 25, 2019, featuring key opinion leaders (KOLs) who are authors of imetelstat data presentations being made at the 24th Annual Congress of the European Hematology Association (EHA). The KOLs will reprise the presentations made at EHA, and Geron’s management team will provide an update regarding progress towards the Company’s 2019 objectives, including the opening of the planned Phase 3 portion of IMerge for screening and enrollment in the summer of 2019. Uwe Platzbecker, M.D., Director, Medical Department I – Hematology and Cell Therapy, University of Leipzig Medical Center, Leipzig, Germany, will review efficacy and safety data presented at EHA from the Phase 2 portion of IMerge, the ongoing Phase 2/3 clinical trial of imetelstat in patients with lower risk myelodysplastic syndromes.
- Benzinga
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Biotech stocks staged a steady recovery last week. ASCO presentations dominated the headlines, with Iovance Biotherapeutics Inc (NASDAQ: IOVA ) and Mirati Therapeutics Inc (NASDAQ: MRTX ) among the biggest ...
- Zacks
Why Is Geron (GERN) Down 22% Since Last Earnings Report?
Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Geron Stock Up More Than 50% in 2019 So Far: Here's Why
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
- Motley Fool
Did Geron's Big Announcement Just Go Unnoticed?
Geron hints at a way forward for imetelstat in myelofibrosis, but the market isn't buying it.
- GlobeNewswire
Geron Announces Two Presentations on Imetelstat at Upcoming European Hematology Association Annual Congress
Geron Corporation (GERN) today announced that two abstracts containing clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted for presentation at the 24th European Hematology Association (EHA) Annual Congress to be held in Amsterdam, the Netherlands, from June 13-16, 2019. “We appreciate the opportunity to present additional data and analyses at EHA from the ongoing imetelstat clinical trials,” said John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer.
- GlobeNewswire
Geron Provides Imetelstat Program Update
Geron Corporation (GERN) today provided an update to its 2019 corporate objectives for the imetelstat program. “2019 is off to a good start with the imetelstat IND transfer now complete, enabling us to move forward with the planned opening of the Phase 3 clinical trial in lower risk myelodysplastic syndromes for screening and enrollment, which we continue to expect by mid-year 2019,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer. “Our new development team has refined our regulatory strategies for myelofibrosis, which we plan to discuss at an End of Phase 2 meeting with the FDA by the end of the first quarter of 2020.
- GlobeNewswire
Geron Continues to Build Senior Leadership of Its Development Team
Geron Corporation (GERN) today announced that it is continuing to build the senior leadership of its development team with the addition of a Vice President, Biometrics, and a Vice President, Manufacturing.
- Zacks
Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up
Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.
